The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2018 | How should MRD be used for MM in routine clinical practice?
There are currently no concrete guidelines for how to use measurable residual disease (MRD) status to inform treatment decisions in multiple myeloma (MM). In this video, recorded at the 23rd congress of the European Hematology Association (EHA) 2018, held in Stockholm, Sweden, Bruno Paiva, PhD, of the University of Navarra, Navarra, Spain, gives his opinion on how MRD should be utilized in routine clinical practice for MM. Dr Paiva emphasizes the use of MRD as one of a suite of diagnostic and prognostic tests that should be carried out, saying it should be used to inform clinicians’ overall understanding of a patient’s disease and treatment.
